Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.74 EUR | +1.82% | +1.90% | -30.41% |
May. 31 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
May. 31 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.41% | 1.84B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- GLPG Stock
- News Galapagos NV
- JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating